Radišić Vanja, Ždraljević Mirjana, Perić Stojan, Mladenović Branka, Ralić Branislav, Jovanović Dejana R, Berisavac Ivana
Neurology Clinic, University Clinical Center of Serbia, Dr. Subotic Street 6, 11 000 Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, Dr. Subotic Street 8, 11 000 Belgrade, Serbia.
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):54. doi: 10.1186/s41983-022-00486-6. Epub 2022 May 15.
Since the outbreak of the coronavirus disease 2019 (COVID-19), an increasing number of Guillain-Barré syndrome (GBS) cases following the infection has been reported. The aim of our study was to detect patients with GBS treated in our hospital over a 1-year period and to compare the characteristics and outcomes of those triggered by COVID-19 with the rest of GBS patients. Our prospective study included 29 patients who were diagnosed with GBS from March 2020 to March 2021. Based on the preceding event, patients were stratified as post-COVID-19 and non-COVID-19. The GBS disability scale (GDS) was used to assess functional disability.
We identified 10 (34.5%) patients with post-COVID-19 GBS and 19 (65.5%) patients with non-COVID-19 GBS. The median time from the preceding event to the symptoms onset was longer in post-COVID-19 than in non-COVID-19 GBS patients ( = 0.04). However, the time from the symptom onset to the nadir did not differ ( = 0.12). GDS at admission, as well as at nadir, did not differ between these two groups. The level of proteinorrachia was higher in post-COVID-19 GBS patients ( = 0.035). The most frequent subtype of GBS in both groups was acute inflammatory demyelinating polyneuropathy (AIDP). GDS score at discharge ( = 0.56) did not differ between two study groups.
There was no difference in clinical and electrophysiological features, disease course, and outcome in post-COVID-19 compared with non-COVID-19 GBS patients.
自2019年冠状病毒病（COVID-19）疫情爆发以来，感染后吉兰-巴雷综合征（GBS）病例的报告数量不断增加。我们研究的目的是检测我院在1年期间接受治疗的GBS患者，并比较由COVID-19引发的GBS患者与其他GBS患者的特征和结局。我们的前瞻性研究纳入了2020年3月至2021年3月期间被诊断为GBS的29例患者。根据先前事件，将患者分为COVID-19后组和非COVID-19组。采用GBS残疾量表（GDS）评估功能残疾情况。
我们确定了10例（34.5%）COVID-19后GBS患者和19例（65.5%）非COVID-19 GBS患者。COVID-19后GBS患者从先前事件到症状出现的中位时间比非COVID-19 GBS患者更长（=0.04）。然而，从症状出现到最低点的时间没有差异（=0.12）。这两组患者入院时以及最低点时的GDS没有差异。COVID-19后GBS患者的脑脊液蛋白水平更高（=0.035）。两组中最常见的GBS亚型均为急性炎症性脱髓鞘性多发性神经病（AIDP）。两个研究组出院时的GDS评分没有差异（=0.56）。
与非COVID-19 GBS患者相比，COVID-19后GBS患者在临床和电生理特征、病程及结局方面没有差异。
